Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accounts Payables: 2018-2025

Historic Accounts Payables for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $12.7 million.

  • Bicycle Therapeutics' Accounts Payables rose 121.44% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year increase of 121.44%. This contributed to the annual value of $15.8 million for FY2024, which is 21.02% up from last year.
  • Per Bicycle Therapeutics' latest filing, its Accounts Payables stood at $12.7 million for Q3 2025, which was down 30.72% from $18.3 million recorded in Q2 2025.
  • Bicycle Therapeutics' Accounts Payables' 5-year high stood at $18.3 million during Q2 2025, with a 5-year trough of $996,000 in Q1 2021.
  • Its 3-year average for Accounts Payables is $9.8 million, with a median of $8.5 million in 2023.
  • As far as peak fluctuations go, Bicycle Therapeutics' Accounts Payables plummeted by 77.54% in 2021, and later skyrocketed by 301.51% in 2022.
  • Over the past 5 years, Bicycle Therapeutics' Accounts Payables (Quarterly) stood at $2.7 million in 2021, then skyrocketed by 137.85% to $6.5 million in 2022, then surged by 101.64% to $13.1 million in 2023, then grew by 21.02% to $15.8 million in 2024, then surged by 121.44% to $12.7 million in 2025.
  • Its last three reported values are $12.7 million in Q3 2025, $18.3 million for Q2 2025, and $11.1 million during Q1 2025.